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Abstract
Background: Within the UK, injecting in the femoral vein (FV), often called ‘groin injecting’, is a serious cause of
risk and harm. This study aimed to use ultrasound scanning as a means to engage groin injectors (GIs), examine
their femoral injecting sites and assess their venous health, with the intention of developing improved responses.
Methods: Between September 2006 and March 2009, GIs attending a network of community drug treatment
centres in South East England were invited to attend an ultrasound ‘health-check’ clinic. This paper provides a
narrative account of the scanning procedure and operation of the service, with descriptive statistical analysis of GIs
who attended. The analysis uses a structured, specially-developed clinical data set that incorporates a
categorisation for the severity of FV damage. Case studies using ultrasound images and a link to a video are
provided to illustrate the range of presentations encountered and the categorisations used for severity.
Results: A total of 160 groin scans (76 bilateral and 8 unilateral) were performed in 84 GIs. The majority were men
(69.0%) and the mean age of the sample was 36.8 years. The mean duration of drug use and injecting drug use
was 19.7 years and 13.8 years, respectively. FV damage at the injecting site in the right groin was graded as
minimal in 20 patients (25%), moderate in 27 (33.8%), severe in 16 (20.0%) and very-severe in 17 (21.3%).
Corresponding figures for left FV were 24 (30.0%), 22 (27.5%), 18 (22.5%) and 16 (20.0%). Wide variation was
observed in the time to the development of these grades of FV damage.
Conclusions: Modern, portable ultrasound scanners make it possible to examine the venous health of GIs in
community treatment settings. Ultrasound scanning identified extensive FV damage, much hitherto-unrecognised
in this population. These findings should further alert clinicians, policy-makers and patients to the urgent need for
effective harm reduction responses to GI behaviour. Images of damaged FV in this paper might prove to be a
useful resource for discussions about GI risks.
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Background
It is estimated that between 100,000 to 150,000 people
currently inject drugs in England [1,2]. Investigations of
samples from this population suggest that between a
third and one half use the femoral vein (FV) in the
groin as their main injecting site [3-5]. Groin injecting
(GI) is associated with significant risks of injury to the
FV and femoral artery (FA) and bacterial and blood
borne viral infections [6]. More serious medical compli-
cations such as deep vein thrombosis (DVT), pulmonary
embolism, chronic venous disease (CVD) and compro-
mise to the adjacent FA with consequent risk of gang-
rene have also been reported [7-10]. Groin injectors
(GIs) are often unaware of these risks and consequently,
tend to present late for treatment of injecting complica-
tions [5]. Hospitalisation of drug users for infections
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has recently increased in England [11]. Cessation of GI
is related to greater treatment retention, but is also a
function of more severe venous disease [12]. This sug-
gests that innovative approaches are needed, which can
better engage people who inject in the FV, so that pro-
blems can be recognised and responded to more quickly
and earlier cessation of GI can be promoted.
Ultrasonography is a non-invasive procedure for inves-
tigating venous and arterial diseases [13]. Ultrasound
scanners use high frequency sound waves to produce
two-dimensional anatomical images and spectral tracings
that can demonstrate vein damage (scarring, narrowing
or blockage by blood clot), arterial damage (e.g. aneur-
ysm) as well as changes in venous and arterial blood
flow. Ultrasonography is safe and the latest scanners are
low cost, portable and capable of producing clear images
[14,15]. Ultrasound scanners are increasingly being used
by non-radiologists to enhance the speed and accuracy of
clinical examinations [16] but the benefits of the technol-
ogy are yet to be evaluated in drug treatment settings.
Some drug treatment services offer harm reduction
advice and information including leaflets to GIs [17,18],
but little is known about their effectiveness [19,20]. In
isolation, simple advice and information that cautions
against GI may have limited efficacy. We hypothesized
that ultrasound scanning might better engage injecting
drug users in discussion about GI risks and help to
improve our understanding of the patho-physiology of
FV damage and CVD among GIs.
The new point-of-care ultrasound service was estab-
lished to provide current and former GIs with easy
access to ultrasound assessment of anatomical and func-
tional status of FV segment at their groin injecting site
(s). Referral pathways to relevant medical and surgical
interventions were identified for patients experiencing
complications of GI. This paper describes:
1. How the service was established, the operation of
the service, the scanning procedure and the characteris-
tics of clinic attendees.
2. The clinical presentation, ultrasound findings and a
grading system for the types of FV damage identified
among GIs.
Methods
The ultrasound equipment
A Macromaxx™ (SonoSite Inc., Bothell, WA, USA) por-
table ultrasound scanner was purchased along with 2
broad-band transducers - a high frequency (5 - 10
MHz) flat linear array probe (L38e) and a low frequency
(2 - 5 MHz) curved linear array probe (C60e). The scan-
ner weighs 3.9 kg with the battery and the C60e trans-
ducer attached. Direct costs of the equipment in 2006
were £23,500 ($40,000).
Operation of the service
The service was offered as a ‘health check’ for opioid-
dependent GIs attending a network of community-based
drug treatment centres in South East England. Posters
and information leaflets based on the recommendations
of the Royal College of Radiologists [21] were displayed
in clinic waiting rooms. We developed a scanning proto-
col in line with the recommendations of the British
Medical Ultrasonography Society [14], new forms for
recording relevant clinical data and a chaperone policy.
Enquiry about GI occurs at assessment and patients
who wish to be scanned attend the ultrasound clinic at
the drug service centre. Forty minutes is allocated for
the interview, scanning and the ‘feedback’ of ultrasound
findings; and the person’s key worker generally serves as
the chaperone. Verbal and written information are pro-
vided and patient participation is voluntary. Written
consent is obtained prior to examination of the groin,
limbs and the scanning.
The scanning procedure and ultrasound anatomy of the
femoral vessels
Scanning is performed with the patient lying on a
couch, the body and head raised up and the limb to be
examined flexed and rotated at the hip in a slight ‘frog-
leg’ position. Coupling gel is applied and scanning starts
at the GI site with the L38e probe placed lightly over
the skin in the transverse plane. The size and anatomi-
cal arrangement of the femoral vessels are noted. In the
groin, the FV is normally larger, medial and at the same
depth as the FA (Figure 1). With the transducer turned
into the longitudinal plane, blood flow is assessed at the
GI site using the duplex or colour Doppler functions of
the scanner (Figure 2). The probe is then allowed to
Figure 1 Vein with minimal damage (grade 1). B-mode image of
the left femoral vein (lcfv) and artery (lcfa) in a 30-year old groin
injector (case study B). The damage to this vein is minimal (grade
1).
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ing note of important landmarks: the sapheno-femoral
junction (image not shown) and the level of the division
of the FA. After dividing, the FA tends to roll on top of
(anterior to) the FV (Figure 3). Starting from the groin,
the probe is pressed into the skin at intervals of 2 cm to
check for FV patency. Full compression should be possi-
b l ew i t hn o r m a lv e i n s( F i g u r e4 )a n da n yr e s i d u a ln o n -
compression may indicate presence of blood clot (Fig-
ures 5 and 6 and case study A). In the middle third of
the thigh, the FV lies deep (behind) the FA (Figure 6). A
video of the scanning procedure may be viewed online
at http://www.kcl.ac.uk/iop/depts/addictions/research/
drugs/FemoralInjecting.aspx
This video file illustrates aspects of the clinical consul-
tation within the ultrasound ‘health check’ clinic. Please
note that there are sequences with no sound.
Figure 2 Normal venous flow (grade 1). Duplex scan showing
normal blood flow - colour flow (top half) and spectral tracing
(lower half) in the left femoral vein (lcfv) of the patient in figure 1
(case study B). Note the normal, phasic venous flow with respiration
(arrows).
Figure 3 Femoral artery anterior to femoral vein. B-mode image
taken 3 cm below the right inguinal ligament in a 24-year old groin
injector. Note that the femoral artery has divided into the femoral
artery of the thigh (rsfa) and the profundus (deep) artery of the
thigh (rdfa).
Figure 4 Fully compressible, normal vein (grade 1). Dual-frame
image of the left femoral vein (lcfv) and artery (lcfa) in a 44-year old
groin injector who has never injected in the lcfv. Patency of the lcfv
is demonstrated by the complete collapse of the vein with
transducer pressure (long arrow). Note the post-acoustic shadows
(short arrows).
Figure 5 Non-compressible vein (dual frame). Dual-frame image
of the left femoral vein (lcfv) and artery (lcfa) in a 31-year old
woman (case study A). The lcfv is non-compressible (long arrow)
suggestive of acute deep vein thrombosis (DVT). Note the
enhanced echo pattern in the soft tissue caused by oedema and
the absence of post-acoustic shadow (small arrow).
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FV damage in each groin is scored as one of four
grades. These are based on the anatomical size and
compressibility of the vein and the blood flow.
￿ Grade 1 (minimal or no change) -F Vi sl a r g e r
than the FA (Figure 1), shows normal flow rate and
pattern (Figure 2) and is fully compressible (Figure 4
and case study B).
￿ Grade 2 (moderate damage) -F Vi sa b o u tt h e
same size as the FA (Figure 7), fully or partially
compressible and shows minor abnormalities in flow
rate or pattern (Figure 8 and case study C).
￿ Grade 3 (severe damage) - FV is smaller than the
FA (Figure 9) and shows significant reduction in
flow rate and a continuous flow pattern (Figure 10
and case study D).
￿ Grade 4 (very-severe damage) -F Vi sm u c h
smaller than the FA (Figure 11). Blood flow may not
be detected in the sclerosed vein but may be present
in collateral veins (Figure 12 and case study E).
Results
Initial uptake of the service
Between September 2006 and March 2009, 84 of 86
(97.7%) GIs had femoral ultrasound scan in the ‘health-
check’ clinic. Two clinic attendees preferred not to have
the scan. Scanning was bilateral in the majority (90.5%)
but 8 patients (9.5%) who had injected drugs in one
groin but has never done so in the other groin had
unilateral scan. A total of 160 groin scans have thus
been conducted.
Patient characteristics
The participants were predominantly male (69.0%) and
white European (96.4%). The mean ± SD (range) age,
duration of drug use and IDU were 36.8 years ± 8.6 (21
- 56), 19.7 years ± 8.3 (4 - 39) and 13.8 years ± 7.9 (2 -
33), respectively. Opioid substitution treatment (OST)
was in the form of methadone oral solution (75/84,
Figure 6 Non-compressible vein (B mode).B - m o d ei m a g eo fa
non-compressible left femoral vein (lsfv, see arrow) behind the
femoral artery (lsfa) in the thigh of the patient in figure 5 (case
study A), indicative of extension of the blood clot to the femoral
vein in the mid-thigh.
Figure 7 Vein with moderate damage (grade 2).D u a l - f r a m e
image and compression test in a 36-year old man (case study C). A
sinus (short arrows) is seen above the right femoral vein (rcfv)
which is not fully compressible (long arrow). This vein damage was
graded as moderate (grade 2).
Figure 8 Venous flow with minor abnormality (grade 2). Colour
flow image from the right femoral vein (rcfv) of the patient in
figure 7 (case study C). Note that venous blood flow (as indicated in
colour flow image) beneath the sinus remains satisfactory (arrow).
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oxone (7/84, 8.3%). Two patients (2.4%) commenced
OST after the scanning. Mean time in treatment was 1.8
years (SD 2.3, range 0 - 10). Of the 84 participants, 37
( 4 4 . 0 % )h a dn o ti n j e c t e di nt h eF Vf o ra tl e a s to n e
month and 47 (56.0%) reported ongoing drug use by GI.
Table 1 shows the drugs ‘ever’ injected and the drugs
currently being injected in the FV.
Clinical presentation
The presenting symptoms and the physical findings
w e r ea ss h o w ni nt a b l e2 .H a l fo ft h es a m p l e( 4 7 . 6 % )
reported previous history of DVT in either leg. Leg pain
(54.8%) and swelling (36.9%) were the most common
symptoms and the majority (61.9%) had depressed scar-
ring (sinus) in either groin.
Figure 9 Vein with severe damage (grade 3). Dual-frame image
and compression test in a 43-year old woman (case study D). The
left femoral vein (lcfv, short arrow) is smaller than the artery (lcfa)
and the vein did not collapse completely with compression (long
arrow). The damage to this vein was graded as severe (grade 3).
Figure 10 Vein with reduced, continuous flow (grade 3). Duplex
scan showing significant reduction in blood flow (top half of image)
and continuous venous flow (lower half of image) in the severely
damaged left femoral vein (lcfv) of the patient in figure 9 (case
study D). Compare this reduced, continuous flow with the normal
venous flow pattern in figure 2.
Figure 11 No blood flow, very severe damage (grade 4).D u a l -
frame image from a 37-year old groin injector (see case study E).
The left femoral vein (lcfv) is small and occluded by an echogenic
material (organised blood clot). Note the absence of post-acoustic
shadow behind the vein (arrows). The damage was graded as very-
severe (grade 4).
Figure 12 Alternative venous drainage, very severe damage
(grade 4). B-mode image showing a very-severely damaged left
femoral vein (lcfv) and new vessels (vv), providing alternative routes
for venous drainage.
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Of the 80 right groin scans, FV damage was graded as
minimal in 20 (25.0%), moderate in 27 (33.8%), severe in
16 (20.0%), and very-severe in 17 (21.3%). The corre-
sponding figures for the left groin were 24 (30.0%), 22
(27.5%), 18 (22.5%) and 16 (20.0%). No evidence of
aneurysm or abnormal blood flow in the FA was
detected in this sample.
Time to development of FV damage
Time to FV damage was estimated systematically on the
basis of the clinical history. Duration since first GI was
noted and then adjusted to reflect subsequent periods
(months) of GI cessation e.g. during imprisonment or in
connection with OST or detoxification. Estimated dura-
tion varied widely, ranging from 1 to 116 months (med-
ian, 31 months) for GIs with minimal damage. The
corresponding figures for moderate, severe and very-
severe FV damage were 6 to 234 months (48 months), 9
to 180 months (60 months) and 12 to 240 (48 months)
respectively.
Case studies
Case study A
A 31-year old woman presented in the clinic with 2-
week history of pain and swelling in her left lower limb
for which she was prescribed antibiotics. She has been
injecting heroin regularly in her left groin for one year.
Ultrasound scan revealed a non-compressible left FV at
the injecting site (Figure 5) suggestive of acute DVT
with extension of the blood clot to the FV in the middle
third of the thigh (Figure 6). She was immediately
referred to the Accident and Emergency department.
Case study B
This asymptomatic 30-year old man has been injecting
heroin intermittently in the left groin for 5 years. Ultra-
sound scan showed a normal-sized, fully compressible
FV (Figure 1) with normal venous flow rate and pattern.
The ‘phasic’ flow pattern in Figure 2 indicates absence
of outflow obstruction from the vein. The damage to
this FV was graded as minimal. Personalised feedback
Table 1 Drugs used by injection and the injecting site among 84 clinic attendees
Substance Route used for self administration by injection
Current injection drug use
Ever injected in the groin
N (%)
Injection in the groin
N (%)
Injection in surface vein
N (%)
Heroin (n = 84) 84 (100.0%) 47 (56.0%) 8 (9.5%)
Cocaine
(Crack/powder, n = 83)
59 (71.1%) 20 (24.1%) 5 (6.0%)
Snowball (combined heroin and cocaine, n = 76) 40 (52.6%) 14 (18.4%) 1 (1.3%)
Amphetamines (n = 69) 18 (26.1%) - -
Benzodiazepines (crushed tablets and/or ampoules, n = 69) 8 (11.6%) - -
Methadone ampoules (n = 69) 4 (5.8%) - -
Crushed tabs (n = 69)
Codeine 3 (4.3%) - -
Diconal (dipipanone/cyclizine) 3 (4.3%) - -
Ecstasy 2 (2.9%) - -
Buprenorphine (Temgesic) 1 (1.4%) - -
Palfium 1 (1.4%) - -
Alcohol (n = 69) 1 (1.4%) - -
Table 2 Medical history, presenting symptoms and
clinical findings among 84 groin injectors
Right (n =
80)
N (%)
Left (n =
80)
N (%)
Either (n =
84)
N (%)
Medical history
Lower limb DVT 30 (38.0%) 32 (41.0%) 39 (47.6%)
Presenting symptoms
Leg pain 31 (38.8%) 28 (35.0%) 46 (54.8%)
Leg swelling 23 (28.8%) 17 (21.3%) 31 (36.9%)
Physical signs
Groin
Puncture/track mark 12 (15.0%) 9 (11.3%) 10 (11.9%)
Flat scar 21 (26.3%) 16 (20.0%) 17 (20.2%)
Depressed scar 43 (53.8%) 43 (53.8%) 52 (61.9%)
Leg
Varicose veins 16 (20.1%) 18 (22.6%) 23 (27.4%)
Oedema 12 (15.0%) 7 (8.8%) 15 (17.9%)
Leg ulcer (open/
healed)
6 (7.5%) 3 (3.8%) 7 (8.3%)
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with clear advice to stop injecting drug use.
Case study C
An asymptomatic 36-year old man who has been inject-
ing heroin and cocaine separately and in combination
(snowball) in the right groin for 12 years. The dual
image in Figure 7 demonstrates a depressed scar (sinus)
at the injecting site with satisfactory blood flow through
the FV (Figure 8). The damage to this FV was graded as
moderate. Risk of further damage with persistent GI was
explained and he was advised to stop GI.
Case study D
This 43-year old woman stopped injecting in the groin
following her second hospital admission for left lower
limb DVT, one year before she attended the clinic. Over
a 15-year period, she had injected heroin, cocaine,
amphetamines, and crushed diconal (dipipanone/cycli-
zine) and diazepam tablets in her groin. The FV is
much smaller than the artery (Figure 9) with reduced
blood flow and a ‘continuous’ flow pattern (Figure 10)
indicating partial outflow obstruction. This FV was
graded as severely damaged. Her feedback included an
explanation of her leg ache/pain.
Case study E
A 37-year old man who has been injecting heroin,
cocaine and ‘snowball’ in both groins for 4 years and is
on life-long warfarin treatment for recurrent bilateral
DVT. He reported having difficulties with ‘finding’ the
FV in his groin. Figure 11 shows a small, sclerosed FV
containing echogenic material (organised blood clot)
with no blood flow. The vein damage was graded as
‘very-severe’. The findings convinced him of the futility
of further GI attempts. New venous ‘channels’ are often
seen in patients with severely damaged FV (Figure 12).
Discussion
Ultrasound scanning identified significant FV damage in
three quarters (72.5%) of the groins examined and two-
fifths (41.8%) of the veins showed ‘severe’ or ‘very-
severe’ damage. Much of the FV damage and functional
(blood flow) impairment identified among our sample of
symptomatic and asymptomatic GIs remain under-
appreciated in terms of its magnitude and impact on
drug users. Vein damage at the GI site has been attribu-
ted to direct trauma from repeated vein puncture [3],
irritating effects of intravenous and peri-vascular injec-
tion of substances [22,23] and septic thrombo-phlebitis
and other local bacterial infections [11]. Future studies
should examine the factors associated with more rapid
FV damage in view of the wide variation in the time to
FV damage observed among GIs in this study and by
other authors [3].
Half of our sample of GIs reported past history of
DVT. The observed association between GI and DVT is
widely recognised in the literature [6,24]. DVT and pul-
monary embolism are amongst the most serious compli-
cations of GI [9]. In addition to the risk of death from
pulmonary embolism, untreated or poorly-treated DVT
often results in sclerosis, narrowing or loss of patency of
veins [3,6]. Sclerosed veins lose their ability to expand
to accommodate increases in venous return during peri-
ods of increased physical activity. Symptoms of venous
insufficiency (leg ache/pain or swelling) were reported
by more than half (54.8%) of GIs in our study. These
symptoms occur at a younger age among GIs compared
with the general population [7,24]. The mean age of our
sample of GIs was 36.8 years.
People who inject drugs in the groin often require
basic information and education about femoral anatomy
and the symptoms of DVT. These factors may contri-
bute to the reported late presentation for treatment of
injecting-related complications [5,11]. Our early experi-
ences of point-of-care ultrasonography suggest that per-
sonalised feedback of ultrasound findings may enhance
patient and key worker (chaperone) awareness of GI
risks. Longer term evaluation of the effectiveness of this
type of intervention is needed. Evaluations of the feasi-
bility and consideration of ethical issues will be required
in order to establish the parameters for any future use
of ultrasound scanners to locate ‘safer’ surface veins in
GIs who cannot be persuaded to stop injecting drug
use.
Ultrasound assessment of FV damage within drug
clinics has training implications. Diagnostic accuracy of
ultrasonography is dependent on the experience of the
operator [14,16]. Our experience suggests that point-of-
care ultrasound services for injecting drug users have
potential use for detecting FV damage at an earlier
stage, rather than as an alternative to hospital-based
radiology services. Point-of-care ultrasound service for
GIs should therefore be used for the purposes of attract-
ing, assessing and educating drug users about GI risks;
and potentially, for promoting behaviour change.
Patients presenting with symptoms, signs or ultrasound
findings suggestive of DVT should immediately be
referred to acute or emergency services.
Provision of a clinical health check with basic ultra-
sound scan of femoral vessels is evidently feasible within
community-based drug clinics. The participants were
concerned about GI risks and keen to identify the extent
of any existing FV damage. By providing access to ultra-
sonography within familiar settings, we were able to
attract and engage GIs in detailed assessment of their
venous health. It is unlikely that most of these GIs
would otherwise have presented to hospital radiology
department for this assessment. Ultrasound scanning
within drug clinics might thus provide greater opportu-
nities for improving our understanding of GI practices
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associated with the behaviour.
Conclusions
The strength of ultrasound imaging lies in its safety,
non-invasive nature and comparatively low cost. Such
vascular ultrasonography delivered at the point-of-care
for injecting drug users has identified extensive damage,
much hitherto-unrecognised, which has alerted both
patients and clinicians to issues requiring urgent atten-
tion. The new clinical service has proved popular and
m a yb eav a l u a b l et o o lf o rd e t e c t i n gm o r b i d i t ya ta n
early stage. Longer term evaluation of its effectiveness as
a harm reduction intervention among patients who
inject in the FV is now needed.
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